JP6692755B2 - アルツハイマー病（ａｄ）の処置および予防 - Google Patents

アルツハイマー病（ａｄ）の処置および予防 Download PDF

Info

Publication number
JP6692755B2
JP6692755B2 JP2016565267A JP2016565267A JP6692755B2 JP 6692755 B2 JP6692755 B2 JP 6692755B2 JP 2016565267 A JP2016565267 A JP 2016565267A JP 2016565267 A JP2016565267 A JP 2016565267A JP 6692755 B2 JP6692755 B2 JP 6692755B2
Authority
JP
Japan
Prior art keywords
aluminum
pharmaceutical composition
composition according
patients
oxyhydroxide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016565267A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017518275A5 (https=
JP2017518275A (ja
Inventor
マルクス・マントラー
アヒム・シュネーベルガー
アルネ・フォン・ボニン
フランク・マットナー
ヴァルター・シュミット
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Affiris AG
Original Assignee
Affiris AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Affiris AG filed Critical Affiris AG
Publication of JP2017518275A publication Critical patent/JP2017518275A/ja
Publication of JP2017518275A5 publication Critical patent/JP2017518275A5/ja
Application granted granted Critical
Publication of JP6692755B2 publication Critical patent/JP6692755B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/08—Oxides; Hydroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2016565267A 2014-04-29 2015-04-29 アルツハイマー病（ａｄ）の処置および予防 Active JP6692755B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP14166354.2 2014-04-29
EP14166354 2014-04-29
EP14166355.9 2014-04-29
EP14166355 2014-04-29
PCT/EP2015/059339 WO2015165966A1 (en) 2014-04-29 2015-04-29 Treatment and prevention of alzheimer's disease (ad)

Publications (3)

Publication Number Publication Date
JP2017518275A JP2017518275A (ja) 2017-07-06
JP2017518275A5 JP2017518275A5 (https=) 2018-05-31
JP6692755B2 true JP6692755B2 (ja) 2020-05-13

Family

ID=53039896

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016565267A Active JP6692755B2 (ja) 2014-04-29 2015-04-29 アルツハイマー病（ａｄ）の処置および予防

Country Status (18)

Country Link
US (1) US10478454B2 (https=)
EP (2) EP3137093B1 (https=)
JP (1) JP6692755B2 (https=)
KR (1) KR102388363B1 (https=)
CN (1) CN106659738B (https=)
AU (1) AU2015254663B2 (https=)
CA (1) CA2946928C (https=)
CY (1) CY1119674T1 (https=)
DK (1) DK3137093T3 (https=)
ES (2) ES2824763T3 (https=)
HR (1) HRP20171896T1 (https=)
HU (1) HUE037501T2 (https=)
LT (1) LT3137093T (https=)
NO (1) NO3137093T3 (https=)
PL (1) PL3137093T3 (https=)
PT (1) PT3137093T (https=)
SI (1) SI3137093T1 (https=)
WO (1) WO2015165966A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3137094T3 (pl) * 2014-04-29 2023-03-13 Advantage Therapeutics, Inc. Leczenie i profilaktyka choroby alzheimera (ad)
EP3137097B1 (en) 2014-04-29 2023-06-21 ADvantage Therapeutics, Inc. Treatment and prevention of alzheimer's disease (ad)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994016327A1 (en) * 1993-01-14 1994-07-21 Pollard Harvey B Methods and compositions for blocking amyloid protein ion channels
HUP0004331A3 (en) * 1997-08-21 2001-09-28 Gerolymatos P N Sa Use of phanquinone for producing pharmaceutical compositions for the treatment of alzheimer's disease and combined pharmaceutical compositions containing it
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
BR112012024708A2 (pt) * 2010-03-29 2016-06-07 Novartis Ag composição de compostos orgânicos
PL3137094T3 (pl) * 2014-04-29 2023-03-13 Advantage Therapeutics, Inc. Leczenie i profilaktyka choroby alzheimera (ad)
EP3137097B1 (en) * 2014-04-29 2023-06-21 ADvantage Therapeutics, Inc. Treatment and prevention of alzheimer's disease (ad)

Also Published As

Publication number Publication date
AU2015254663B2 (en) 2020-04-02
US20170049812A1 (en) 2017-02-23
EP3269376A1 (en) 2018-01-17
EP3137093B1 (en) 2017-09-13
CA2946928C (en) 2023-01-31
CN106659738A (zh) 2017-05-10
EP3137093A1 (en) 2017-03-08
EP3269376B1 (en) 2020-07-15
AU2015254663A1 (en) 2016-11-10
ES2824763T3 (es) 2021-05-13
SI3137093T1 (en) 2018-01-31
CY1119674T1 (el) 2018-04-04
CN106659738B (zh) 2021-02-09
CA2946928A1 (en) 2015-11-05
HUE037501T2 (hu) 2018-08-28
HRP20171896T1 (hr) 2018-02-23
PL3137093T3 (pl) 2018-06-29
DK3137093T3 (en) 2017-12-11
US10478454B2 (en) 2019-11-19
LT3137093T (lt) 2017-12-11
KR20160145822A (ko) 2016-12-20
ES2651537T3 (es) 2018-01-29
KR102388363B1 (ko) 2022-04-19
NO3137093T3 (https=) 2018-02-10
JP2017518275A (ja) 2017-07-06
WO2015165966A1 (en) 2015-11-05
PT3137093T (pt) 2017-12-19

Similar Documents

Publication Publication Date Title
US20220062412A1 (en) Treatment of alzheimer's disease (ad) with an aluminum salt
US20240148782A1 (en) Treatment and prevention of alzheimer's disease (ad)
JP6692755B2 (ja) アルツハイマー病（ａｄ）の処置および予防

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180410

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180410

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190205

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190426

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190701

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A132

Effective date: 20191001

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191218

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200317

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200415

R150 Certificate of patent or registration of utility model

Ref document number: 6692755

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250